Multiple Myeloma and Renal Failure - European Medical Journal

Multiple Myeloma and Renal Failure

Download PDF
*Patrizia Tosi, Manuela Imola, Anna Maria Mianulli, Simona Tomassetti, Annalia Molinari, Serena Mangianti, Marina Ratta, Anna Merli, Valentina Polli

No potential conflict of interest.

EMJ Oncol. ;3[1]:65-69. DOI/10.33590/emjoncol/10312540.
Myeloma, renal failure, light chains.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.


Renal failure (RF) occurs in approximately 20-30% of multiple myeloma (MM) patients at diagnosis and in more than 50% of patients with advanced disease. The pathogenesis of RF is related to the production of monoclonal light chains that can damage either the tubule (myeloma kidney) or the glomeruli (light chain deposition disease or amyloid light-chain amyloidosis). In the past, the prognosis of patients with  MM and RF was considered poor due to the limited number of effective and non-nephrotoxic drugs that were available. At present, novel drugs acting both on MM clone and on bone marrow microenvironment have been introduced into clinical practice; among them, bortezomib-containing regimens have proved  to be the most effective. High-dose myeloablative therapy followed by autologous stem cell rescue can  also be proposed in younger patients with no other relevant comorbidities.

Please view the full content in the pdf above.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now